You are here: Home / Archives for Market

Global Engineering Services Industry Market Research Report Now Available from IBISWorld

April 24, 2012 By Leave a Comment


Los Angeles, CA (PRWEB) April 22, 2012

The global market for engineering services consists of the work performed by consultant engineering firms along with the in-house services undertaken by construction contractors, manufacturers, government agencies and utility owners. According to IBISWorld industry analyst Anthony Kelly, the industry’s performance is principally driven by the trends into construction, manufacturing and mining developments (particularly in the large industrial economies) and increasingly from work in the fields of technological development and the sustainable environment. Over the past decade the industry has expanded its operations by broadening across a wider range of multidisciplinary services, by the trend towards globalization and through the outsourcing of services by public authorities and major corporations.

The Global Engineering Services industry is one of the largest professional service industries, generating revenue of about $ 530 billion in 2012 (up 3.0% on the previous year), and employing 2.9 million people. Industry value added currently totals $ 318 billion, or 0.6% of the world’s GDP, two-thirds of which represents payments to employees and the balance the industry’s operating profit. The industry’s performance deteriorated during the late 2000s with the onset of recession in several of the largest developed economies and the subsequent decline in construction and industrial production. Despite the current improvement, industry revenue is estimated to average subdued growth by 0.5% per annum over the five years through 2012.

?International trade represents a significant share of industry activity (10.6% of revenue in 2012) and is mainly confined to relatively few large-scale consulting engineering firms that are capable of operating outside national boundaries,? said Kelly. A feature of the industry that has accompanied globalization has been the amalgamation of the larger players to achieve scale economies, broaden the market and strengthen the human and financial resources (consistent with the trend evident in other knowledge-based industries such as accounting, law, advertising and architecture).

The Global Engineering Services industry has a low concentration of ownership, with the four largest companies accounting for about 6.0% of annual industry revenue. The largest players in the global market for engineering services include URS Corporation, SNC-Lavalin Group, Bechtel Group, Jacobs Engineering Group, Fluor Corporation, AECOM Technology Corporation, CH2M HILL Companies, WS Atkins plc, and Altran Technologies. Despite this low concentration, there has been a trend over the past decade for the consolidation of the operations of many of the world’s leading consulting engineering firms, through mergers or strategic alliances. These large-scale, multidisciplined, multinational companies are well placed to win contracts in most markets. For more information, visit IBISWorld?s Global Engineering Services in the US industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld

Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

The industry comprises establishments engaged in applying physical laws and principles of engineering in the design, development and use of machines, materials, instruments, structures, processes and systems. The assignments may involve the provision of advice, preparation of feasibility studies, preparation of preliminary and final plans and designs, the provision of technical services on construction and project evaluation.

Industry Performance

Executive Summary

Key External Drivers

Current Performance

Industry Outlook

Industry Life Cycle

Products & Markets

Supply Chain

Products & Services

Major Markets

Globalization & Trade

Business Locations

Competitive Landscape

Market Share Concentration

Key Success Factors

Cost Structure Benchmarks

Barriers to Entry

Major Companies

Operating Conditions

Capital Intensity

Key Statistics

Industry Data

Annual Change

Key Ratios

About IBISWorld Inc.

Recognized as the nation?s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.







Related Wellness Press Releases

Filed Under: Wellness Tagged With: , , , , , , , , ,

Global Neurodegenerative Drugs Market to Exceed $43.4 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

March 23, 2012 By Leave a Comment

San Jose, CA (PRWEB) April 12, 2010

Neurodegenerative diseases, caused due to neuron deficiency or dysfunction of the spinal cord or brain cells, are destructive in nature, as regeneration of affected cells is not possible and results in ultimate damage or death. Major neurodegenerative diseases with significant unmet medical needs include Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington’s disease. There are only a few treatment available for some of these diseases, and several of these treatment options provide only symptomatic relief. For a few others such as the Huntington’s disease, there is still not a single therapy available that can treat the disease.

The United States dominates the world neurodegenerative drugs market as stated by the new market research report on Neurodegenerative Drugs market. The market exhibits huge potential considering the high rates of prevalence of Alzheimer’s and Parkinson’s disease. The market is largely untapped due to under-diagnosis owing to lack of proper diagnostics, and lack of therapies that can effectively and safely prevent or treat the diseases.

Multiple Sclerosis represents the largest segment of the neurodegenerative drugs market. The multiple sclerosis drugs market is all set for a major transformation with new drugs in pipeline awaiting approval in near future. Most pipeline drugs are showing promising results in terms of reducing disease progression and other end-points compared to existing drugs. The most promising multiple sclerosis candidates include oral therapies such as Sanofi-aventis’ Teriflunomide, Active Biotech’s Laquinimod, Merck’s Cladribine and Novartis’ FTY720.

Alzheimer’s is the fastest growing segment of the neurodegenerative drugs market. The currently available drugs for Alzheimer’s disease not only provide limited efficacy, but may also result in serious adverse effects. There are issues with acceptability and safety, and some patients may even fail to respond to treatment with available drugs. The outlook appears interesting considering that a few leading products are lined up for patent expiry, including Namenda and Exelon, while there are others in pipeline that promise to deliver on the failure of available therapies.

Key players profiled in the report include Amarin Corporation Plc; AstraZeneca Plc; Avanir Pharmaceuticals Inc.; Avigen Inc.; Bayer Schering Pharma AG; Boehringer Ingelheim GmbH; Biogen Idec Inc.; Bristol-Myers Squibb Co.; Biovail Corporation; Ceregene, Inc.; Eisai, Inc.; Elan Pharmaceuticals; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline plc; H. Lundbeck A/S; Merz Pharmaceuticals GmbH; Merck Serono; Mitsubishi Tanabe Pharma Corporation; Neurologix, Inc.; NeuroSearch A/S; Novartis AG; Pfizer Inc.; Sanofi-aventis S.A.; Shire Pharmaceuticals Group Plc; Teva Pharmaceutical Industries Limited; Valeant Pharmaceuticals International; and Wyeth Pharmaceuticals, Inc.

The report titled “Neurodegenerative Drugs: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, market drivers, market inhibitors, competitive scenario, clinical trials, product introductions/approvals, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe and Rest of World. The study analyzes market data and analytics in terms of value sales for neurodegenerative drugs by disease type, including Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Diseases.

For more details about this comprehensive market research report, please visit -

http://www.strategyr.com/Neurodegenerative_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Web Site http://www.StrategyR.com/

###





Find More Alzheimer Disease Press Releases

Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , ,

CBDM.T

March 18, 2012 By Leave a Comment


Paris, France (PRWEB) April 28, 2010

Dry eye disease (DED) is one of the most frequently encountered ocular morbidities. 25 % percent of patients who visit ophthalmic clinics report symptoms of dry eye, making it a growing public health problem and one of the most common conditions seen by eye care practitioners. Dry eye affects an estimated 20 to 30 million people in the United States and is one of the most common reasons that people visit their eye doctor. Dry eye?s prevalence estimation is very variable but we could estimate that more than 70 million people are or will be affected by dry ocular symptoms. According to CBDM.T, Dry Eye represents one of the fastest growing pharmaceutical product categories in the ophthalmology market at over 10% growth per annum to 2014. The market potential for dry eye drugs is projected to reach 1 billion USD by 2015.

The first line of treatment is usually eye drops that act as artificial tears and give some temporary relief. Restasis (cyclosporine A ophthalmic emulsion) 0.05% is the first approved prescription product in the United States for the treatment of dry eye disease. Restasis (Allergan) sales were 270 million USD in 2006s to 444 million USD by 2008.

In 2008, more than 15 products were under development from discovery, preclinical, clinical phase 1, clinical phase 2 (5 products) to clinical phase 3 with 8 products. The leading companies in this market are Novartis, Alcon (acquired by Novartis), Bausch & Lomb, Vistakon (J&J), Allergan, Pfizer and AMO (Abbott Medical Optics Inc).

According to CBDM.T

Filed Under: Alzheimer's Disease Tagged With: , , , , , , ,

Sex Toy Dave Uses Comedy to Help Himself and Others in the Sex Toy Industry Market to the Mainstream

March 9, 2012 By Leave a Comment

Los Angeles, CA (PRWEB) March 07, 2012

Companies are constantly looking for new ways to introduce their products to wider audiences, and cutting edge marketing techniques are the key to any successful ad strategy. Groupon grew to a billion dollar company in a year with a unique new marketing method. For Adult Products company, the Holy Grail of marketing is being able to seamlessly get their company in front of a mainstream audience. Internet entrepreneur ?Sex Toy Dave,? who is owner of online sex toys sales site http://www.SexToy.com seems to have found that opening and has pioneered the way for others in his business through the use of live comedy shows.

Sex Toy Dave has had many creative marketing ideas. He created the first affiliate program for adult product in 1996, which made his reputation. Recently, he sent the “first vibrator into space.” But he is most famous for appearing in three seasons of Bravo’s hit reality TV show, Millionaire Matchmaker. However, over the past 2 years Dave has been honing his comedy chops on stage in front of live audiences. He started out doing ?open mics? around town and now is hosting comedy shows as well as sharing the stage with some of comedy?s top headliners. He performs in the main room at Hollywood?s Comedy Store, and in his act he shows and makes jokes about adult toys like the Alien Blow up doll and the Obama Dildo.

?Between throwing Hollywood parties, selling sex toys and just getting married with a stripper pole still in the living room, I have a lot of content!? he said about his foray into the comedy world. At the end of his performance he gives away free vibrators and makes jokes about the people who want the toys. Dave’s recent performances include him hosting at The Parlor in Hollywood where Daniel Tosh and Dave Chappelle both performed for Dave’s show. Dave also has a regular running appearance in the main room at the Comedy Store on Sunset. His next performance will be back at the Parlor on March 12, 2012 at 9pm.

On top of performing, Dave has helped other companies in his industry use comedy as a marketing tool. Take for instance the largest manufacturer of sex toys in Europe and a major player here in the states, Fun Factory. In October 2011, through the help of Sex Toy Dave, Fun Factory began sponsoring Sam Tripoli?s ?Naughty Show,? an act that has been hosted at various Hollywood clubs including Voyeur, The Comedy Store and The Viper room. Tripoli had always been notorious for having a raunchy act, and Fun Factory capitalized on this by integrating their brand and products into the show. Tripoli’s show is now a mix of stand-up comedy, skits and interviews with porn stars.

Dave also sponsored former Skid Row drummer Phil Varone?s sex and comedy show. Because of his on stage comedy performances, Varone is the first rock star to come out with a dildo molded from his likeness, and it comes complete with piercing on the tip. He has developed a full line of toys including vibrators shaped like drum sticks and sex toy accessories, and all products are emblazoned with the tag line ?Sex Toys & Rock n Roll.? To promote his sex toys and his celebrity image, Phil runs a comedy show that was initially sponsored by Sex Toy Dave called “Sex, Stand-Up, and Rock and Roll.” The show consists of a live band that plays a few songs and features performances from top stand-up comedians. Phil hosts and has a raffle to get an audience member to come on stage and accept a gift basket full of quality sex toys.

Throughout history, comedy has been used to speak about important subjects in an acceptable way. It seems sex is finding its voice through comedy. Marketing sex toys in a mainstream comedy space seems be a forward thinking and strategic move by Dave. ?I’ve always believed the key to marketing sex toys is to get my personality out to the mainstream. I did that with dating shows and being single. Now that I’m married, I’ve turned to comedy. I perform and now sponsor people. Some day I hope to get back onto Bravo, but this time as a comedian,? says Dave.





Related Wellness Press Releases

Filed Under: Wellness Tagged With: , , , , , , , ,

Leading Korean Brand AK Biotech Introduces the Highest Concentration of Omega-3 to the US Market: Innovative Product can be customized to meet specific business needs

March 4, 2012 By Leave a Comment


New York (Vocus) June 7, 2010

AK Biotech, a leading world supplier of the Omega-3 wonder supplement, is now providing customers in the U.S. with highly concentrated levels of EPA and DHA available in customized ratios of powder, oil and triglyceride. The innovative product line delivers superior Omega-3 benefits and is receiving rave reviews since debuting to more than 3,000 global food and beverage, cosmetic and personal care, and dietary supplement executives from nearly 30 countries at the Supply Side Trade Show in April 2010.

?AK Biotech truly cares about the quality of their product and understands the heightened demand for Omega-3 in its purest form,? says Omega 3 buyer. ?Their ability to deliver such high concentrations of EPA and DHA in customized form will completely satisfy the specific demands of our diverse customer base.?

Omega-3s are increasingly praised for a myriad health benefits. They are credited with helping treat or prevent degenerative illnesses such as heart disease, rheumatoid arthritis, diabetes, and even Alzheimer’s. They also play a key role in brain development and cognitive function and have an effect on skin disorders, high cholesterol, high blood pressure, depression, bipolar disorder and osteoporosis.

?The more we learn about omega-3, the more amazing it seems,? says Marcelle Pick, OB/GYN NP, Co-Founder of Women to Women Clinic. ?Because of their anti-inflammatory properties, omega-3?s have been linked with prevention and treatment of a whole host of health problems?It?s no surprise that omega-3 fatty acids are quickly becoming one of the most researched topics in the scientific community ? and one of the most celebrated among people who care about whole health.?

According to David Valentine, associate professor of earth science at UCSB, Omega-3s are essential fatty acids that the body cannot make by itself. They are obtained largely from fish and other marine life, such as algae and krill. The two omega-3s that provide the clearest health benefits are the ?fish oils” eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). These are the omega-3s that AK Biotech has focused on in their new product, which combines high concentrations of EPA (not less that 70%) and DHA (not less than 80%) to deliver the purest form of Omega-3 to the market.

AK Biotech?s value lies in the pursuit of a thorough and complete quality management system, of which R&D is an integral part. With the construction of a corporate research institute and a state-of-the-art factory with a GMP and HACCP system in Ulsan, the company is positioned to meet any requirement from customers and partners worldwide.

?We are confident in our ability to be a reliable partner to Omega-3 buyers worldwide,? said company spokesperson Mr. Lee. ?Our factory is set up to deliver product of the highest quality, free of contaminants such as PCBs, Dioxin, and heavy metals and without unessential saturated fatty acid. We recognize the value of quality over quantity and not only deliver the highest concentration of Omega-3 but concentrate heavily on R&D. We strive to increase corporate profits through improvements of processes.?

Advance quality control procedures ensure excellence and reliability through continued research, repair and upkeep, including the validation of all equipment and methods used in the laboratory to ensure that they give expected results. Technicians continually work to improve TG synthesis and develop technologies such as oil powderization and low-cost, efficient deodorization. The company maintains all industry certifications (GMP FDA, ISO14001 & 9001, HAACP, HALAL) and has proven capabilities for delivering Omega-3 in every formulation (EPA, DHA, Bulk Oil, Bulk Capsule).

AK Biotech guarantees social responsibility by adhering to clean environmental practices and offering competitive prices without sacrificing quality or customer support. The company only uses ingredients from ecologically clean environments, such as Peru and Thailand, to guarantee the purest form of Omega-3 in their product. Fish oil and other raw materials are only purchased from pre-approved vendors from environmentally clean zones. Technicians investigate raw material suppliers by rigorous standard and certificates of analysis are issued for all products, once quality and compliance are confirmed.

Although AK Biotech is 100% dedicated to providing the purest, highest concentration of Omega-3, it is keenly aware of the multitude of uses for Omega-3 and the need for buyers to meet the demands of various people. According to Nurhan Dunford, FAPC Oil/Oilseed Chemist with the Division of Agricultural Sciences and Natural Resources, large brands such as Nestle and Kellog Company are marketing Omega-3 enriched formulas of mayonnaise, nutrition bars, cream cheese, yogurt, bread, eggs and many other commercial products. Deb Borgan of Sea-Based Health LLC estimates that retail sales of foods and beverages enriched with Omega 3?s will reach more than $ 7 billion by 2011.

?As consumers continue to demand more nutritious products, food manufacturers are seeking many more opportunities to include omega-3 in their formulations,? said Dunford. ?A main reason for omega-3 supplementation in adults is due to an imbalance?It is believed human beings evolved on a diet with a ratio of omega-6/omega-3 fatty acids of about 1. Today the same ratio is in the range of 15/1 to 17/1 in the Western diet.?

The FDA recommends 3g of EPA and DHA per day. AK Biotech is committed to providing customized solutions that allow buyers to deliver the recommended dosage in the formula that best fits their customers? lifestyle.

?Omega-3?s contribute to every inch of our bodies,? said Pick. ?From our hearts to our minds and every cell in-between, I promise omega-3?s are the healthiest fats you can consume! And no matter how busy you are, there are easy ways to include them in your diet.?

To purchase AKBiotech Omega 3, request a quote or set up an appointment please contact Ksenia Denisova at MZI Global 212 366 5409

About http://www.mziglobal.com/ MZI Global]:

MZI Global is the ultimate resource for South Korean products. MZI Global?s Ethnosynergism

Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , , , , ,

Korean Biotechnology Leader AnyGen Launches the Highest Purity Custom-Made and Catalog Peptides in the U.S. Market

December 27, 2011 By Leave a Comment


New York, NY (Vocus) November 4, 2010

Korean Biotechnology leader AnyGen is launching its high-level custom-made and catalogue peptides for the first time in the U.S. AnyGen offers the highest purity peptide available (98% vs. 95% for most competitors). The company is expanding its international presence by importing to various global pharmaceutical giants such as Takeda Pharmaceutical R&D center in Japan.

According to Frost & Sullivan Research, there are currently 40 approved peptide-based drugs in use today, approximately 270 peptides in clinical phase testing, and 400 being developed to treat ailments such as allergies, cancer, Alzheimer’s, Huntington?s, and Parkinson?s diseases. Peptide-based therapies tap into the direct hard wiring of human physiology, yielding substantial and far-reaching benefits.

?Peptide-based drugs offer the advantage of low toxicity, no complications, low therapeutic costs and high-biological activity,? said Dr. Jae-Il Kim, C.E.O., AnyGen. Peptides have the inherent ability to block and/or enhance signal transfers in the human body. Natural peptides such as insulin, vancomycin, oxytocin, and cyclosporine and synthetically produced ones such as Fuzeon (enfuvirtide) and Integrilin (eptifibatide) are among the approved peptide-based drugs.

Peptides are also one of the leading, most coveted, cosmetic ingredients in the anti-aging skincare markets, proven to stimulate collagen production and prevent its breakdown to keep skin firm and smooth.

AnyGen provides various modifications for custom-made peptides and specializes in difficult and long sequences for peptide synthesis. It uses the highest quality ingredients, from pharmaceutical giants Merck and Bachem, to assure customer satisfaction. In January 2011 AnyGen will become the first Korean peptide manufacturer to obtain GMP (Good Manufacturing Practice) status for its mass production facility.

AnyGen is dedicated to the progress of Biotechnology through consistent research and development. The company obtained two ISO (International Organization of Standardization) certifications (ISO 2001, ISO 14001), and the company was awarded the ?INNO-BIZ? award by the Korean government for its innovative products. In 2006, AnyGen successfully completed mass production for pre-clinical and cosmetics peptide.

About AnyGen

AnyGen Co., Ltd. was established as the first Bio-Venture company in 2000 by professors at the Gwangju Institute of Science & Technology (GIST). The company focuses on developing new bio drugs and essential materials based on physiologically active peptides, biologically functional materials, and chemical nano materials.

About MZI Global

MZI Global is a market entry strategy consultancy firm based in New York City serving international inbound clients entering North America and outbound US companies expanding to global markets. MZI Global

Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , ,

IC Markets, Market Leading Forex Broker Launches New Metatrader 4

December 21, 2011 By Leave a Comment


Sydney, Australia (PRWEB) December 20, 2011

International Capital Markets Pty Ltd (IC Markets), one of Australia?s leading and most innovative forex brokers becomes the first broker in the region to offer a fully customised version of the world?s leading forex trading platform, Metatrader 4.

New features of the trading platform include one-click trading. Traders can now trade with a single click in addition to placing default stop-loss and take-profit orders at the same time. A risk and position size calculator, allowing traders to determine their order-size as a percentage of their account with ease. Ability to place OCO orders in one step. Chart based trading which includes moving stop-loss orders and take-profit orders in one click.

Metatrader 4 is the world?s leading forex trading platform allowing retail investors to access the biggest market in the world. Mr Andrew Budzinski, Managing Director of IC Markets said: ?We understand our clients? requirements and are proud to deliver a customised Metatrader 4 forex trading solution to meet their needs?.

?The launch of our new Metatrader 4 platform combined with our most recent acquisition of an Australian based Virtual Private Server (VPS) provider is part of the first stage of our broader 2012 strategy aimed to deliver market leading automated trading solutions and education to our clients.?

A virtual private server (VPS) is much like a physical computer hosted eternally. A VPS provides forex traders with the ability to run automated trading strategies 24 hours a day 7 days a week without the need to leave their computer running and connected to the internet. Using a VPS is a reliable solution for forex traders as it will not reboot during the trading week, and is not affected by power outages.

A demonstration of IC Markets new Metatrader 4 platform can be downloaded from the following link: metatrader demo.

About International Capital Markets Pty Ltd (IC Markets).

Headquartered in Sydney International Capital Markets Pty Ltd is a provider of online forex and CFD trading services, offering individual traders, money managers and institutional customer?s proprietary technology, tools and education to trade online. IC Markets has distinguished itself among industry leaders with its unique ECN forex technology, proprietary tools and services, and remarkable focus on customer service. With turnover well exceeding tens of billions each month the company is one of the leading brokers in Australia. IC Markets is regulated by the Australian Securities and Investments Commission in Australia.

Forex trading may not be suitable for everyone so please ensure that you fully understand the risks involved. Please consider IC Markets PDS available from IC Markets before entering into any transaction with us.

###





Filed Under: Wellness Tagged With: , , , , , ,

Global Genetic Testing Market to Reach US$1.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

November 30, 2011 By Leave a Comment

San Jose, CA (Vocus/PRWEB) January 11, 2011

Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market worldwide. Molecular diagnostics is the fastest growing segment in the In-Vitro Diagnostics (IVD) market. Key factors fostering growth in the molecular diagnostics market include increasing awareness about human genome, newer technologies and innovation for accurate detection and faster screening. With increasing number of aging population globally, countries across the world face the challenge of preventing age-related diseases, such as cardiovascular diseases and diabetes. This indicates the requirement of new diagnostics, including genetic testing. Genetic testing, which of-late has been transforming itself from service-driven to product-driven market, is expected to provide an impetus to diagnostic companies for the expansion of their operations. Advancements in genetic testing field enable physicians to determine patients? health at different stages of the diagnostic treatment process.

Growing incidence of genetic diseases unravels new opportunities for genetic testing. The market is likely to expand for screening the newborns, diagnosing rare and fatal disorders, and predicting the probability of occurrence of diseases, such as Huntington. Genetic tests for newborn screening are expected to expand immensely over the coming years. In addition, with advances in genetic testing procedures, tests would be focused on early detection of Alzheimer disease, hemochromatosis, breast cancer, colorectal cancer, diabetes in young people, and rare forms of amyotrophic lateral sclerosis. Genetic testing identifies finest cancer treatment for specific patients. Advancements in genetic testing, together with genetically engineered drugs, are expected to aid in tailoring personalized medicine for specific races, individuals, and families.

The US represents the largest market for genetic testing worldwide, as stated by the new market research report on Genetic Testing. Genetic counseling services are on the rise, specifically in the US. Presently, there are around 2,780 certified genetic counselors operating in the United States. Direct-to-Consumer genetic testing is expected to open new avenues in the US, for companies looking for areas to further expand their range of screening tests. DTC genetic testing method involves marketing genetic tests directly to consumers without involvement of independent healthcare provider.

The US is witnessing dramatic changes in the DNA-based testing industry, with the advent of transformational technologies, which are extending the scope of complicated genomic and genetic testing into clinical and medical laboratories, which conduct tests on individual patients for identifying genes linked to certain medical disorders.

Major players profiled in the report include Abbott Laboratories, Abbott Molecular Inc., Applied Biosystems Inc., AutoGenomics, Inc., BioRad Laboratories, Celera Group, Clinical Data Inc., Orchid Cellmark Inc., PerkinElmer Inc., Quest Diagnostics Inc., Roche Diagnostics Corp., Roche Molecular Diagnostics Inc. among others.

The research report titled “Genetic Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the genetic testing market, current market trends, key growth drivers, new product innovations/launches, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for the global genetic testing market for the years 2007 through 2015 for the regions, including US, Canada, Japan, Europe, and Rest of World. The report also analyzes the US market for genetic testing by application type – Pharmacogenomic Testing, Prenatal and Newborn Genetic Testing, and Predictive Medicine. Also, a seven-year (2000-2006) historic analysis is provided for additional market perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Genetic_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

# # #





Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , ,

Global Genetic Testing Market to Reach US$1.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

November 29, 2011 By Leave a Comment

San Jose, CA (Vocus/PRWEB) January 11, 2011

Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market worldwide. Molecular diagnostics is the fastest growing segment in the In-Vitro Diagnostics (IVD) market. Key factors fostering growth in the molecular diagnostics market include increasing awareness about human genome, newer technologies and innovation for accurate detection and faster screening. With increasing number of aging population globally, countries across the world face the challenge of preventing age-related diseases, such as cardiovascular diseases and diabetes. This indicates the requirement of new diagnostics, including genetic testing. Genetic testing, which of-late has been transforming itself from service-driven to product-driven market, is expected to provide an impetus to diagnostic companies for the expansion of their operations. Advancements in genetic testing field enable physicians to determine patients? health at different stages of the diagnostic treatment process.

Growing incidence of genetic diseases unravels new opportunities for genetic testing. The market is likely to expand for screening the newborns, diagnosing rare and fatal disorders, and predicting the probability of occurrence of diseases, such as Huntington. Genetic tests for newborn screening are expected to expand immensely over the coming years. In addition, with advances in genetic testing procedures, tests would be focused on early detection of Alzheimer disease, hemochromatosis, breast cancer, colorectal cancer, diabetes in young people, and rare forms of amyotrophic lateral sclerosis. Genetic testing identifies finest cancer treatment for specific patients. Advancements in genetic testing, together with genetically engineered drugs, are expected to aid in tailoring personalized medicine for specific races, individuals, and families.

The US represents the largest market for genetic testing worldwide, as stated by the new market research report on Genetic Testing. Genetic counseling services are on the rise, specifically in the US. Presently, there are around 2,780 certified genetic counselors operating in the United States. Direct-to-Consumer genetic testing is expected to open new avenues in the US, for companies looking for areas to further expand their range of screening tests. DTC genetic testing method involves marketing genetic tests directly to consumers without involvement of independent healthcare provider.

The US is witnessing dramatic changes in the DNA-based testing industry, with the advent of transformational technologies, which are extending the scope of complicated genomic and genetic testing into clinical and medical laboratories, which conduct tests on individual patients for identifying genes linked to certain medical disorders.

Major players profiled in the report include Abbott Laboratories, Abbott Molecular Inc., Applied Biosystems Inc., AutoGenomics, Inc., BioRad Laboratories, Celera Group, Clinical Data Inc., Orchid Cellmark Inc., PerkinElmer Inc., Quest Diagnostics Inc., Roche Diagnostics Corp., Roche Molecular Diagnostics Inc. among others.

The research report titled “Genetic Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the genetic testing market, current market trends, key growth drivers, new product innovations/launches, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for the global genetic testing market for the years 2007 through 2015 for the regions, including US, Canada, Japan, Europe, and Rest of World. The report also analyzes the US market for genetic testing by application type – Pharmacogenomic Testing, Prenatal and Newborn Genetic Testing, and Predictive Medicine. Also, a seven-year (2000-2006) historic analysis is provided for additional market perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Genetic_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

# # #





Related Alzheimer Disease Press Releases

Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , ,

Global Genetic Testing Market to Reach US$1.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

November 29, 2011 By Leave a Comment

San Jose, CA (Vocus/PRWEB) January 11, 2011

Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market worldwide. Molecular diagnostics is the fastest growing segment in the In-Vitro Diagnostics (IVD) market. Key factors fostering growth in the molecular diagnostics market include increasing awareness about human genome, newer technologies and innovation for accurate detection and faster screening. With increasing number of aging population globally, countries across the world face the challenge of preventing age-related diseases, such as cardiovascular diseases and diabetes. This indicates the requirement of new diagnostics, including genetic testing. Genetic testing, which of-late has been transforming itself from service-driven to product-driven market, is expected to provide an impetus to diagnostic companies for the expansion of their operations. Advancements in genetic testing field enable physicians to determine patients? health at different stages of the diagnostic treatment process.

Growing incidence of genetic diseases unravels new opportunities for genetic testing. The market is likely to expand for screening the newborns, diagnosing rare and fatal disorders, and predicting the probability of occurrence of diseases, such as Huntington. Genetic tests for newborn screening are expected to expand immensely over the coming years. In addition, with advances in genetic testing procedures, tests would be focused on early detection of Alzheimer disease, hemochromatosis, breast cancer, colorectal cancer, diabetes in young people, and rare forms of amyotrophic lateral sclerosis. Genetic testing identifies finest cancer treatment for specific patients. Advancements in genetic testing, together with genetically engineered drugs, are expected to aid in tailoring personalized medicine for specific races, individuals, and families.

The US represents the largest market for genetic testing worldwide, as stated by the new market research report on Genetic Testing. Genetic counseling services are on the rise, specifically in the US. Presently, there are around 2,780 certified genetic counselors operating in the United States. Direct-to-Consumer genetic testing is expected to open new avenues in the US, for companies looking for areas to further expand their range of screening tests. DTC genetic testing method involves marketing genetic tests directly to consumers without involvement of independent healthcare provider.

The US is witnessing dramatic changes in the DNA-based testing industry, with the advent of transformational technologies, which are extending the scope of complicated genomic and genetic testing into clinical and medical laboratories, which conduct tests on individual patients for identifying genes linked to certain medical disorders.

Major players profiled in the report include Abbott Laboratories, Abbott Molecular Inc., Applied Biosystems Inc., AutoGenomics, Inc., BioRad Laboratories, Celera Group, Clinical Data Inc., Orchid Cellmark Inc., PerkinElmer Inc., Quest Diagnostics Inc., Roche Diagnostics Corp., Roche Molecular Diagnostics Inc. among others.

The research report titled “Genetic Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the genetic testing market, current market trends, key growth drivers, new product innovations/launches, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for the global genetic testing market for the years 2007 through 2015 for the regions, including US, Canada, Japan, Europe, and Rest of World. The report also analyzes the US market for genetic testing by application type – Pharmacogenomic Testing, Prenatal and Newborn Genetic Testing, and Predictive Medicine. Also, a seven-year (2000-2006) historic analysis is provided for additional market perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Genetic_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

# # #





Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , ,
« Older Posts